tetano
Editor, Senior Moderator
Infection
. 2021 Aug 18.
doi: 10.1007/s15010-021-01685-8. Online ahead of print.
A cost of illness study of COVID-19 patients and retrospective modelling of potential cost savings when administering remdesivir during the pandemic "first wave" in a German tertiary care hospital
Julia Jeck[SUP] 1 [/SUP], Florian Jakobs[SUP] 1 2 3 [/SUP], Anna Kron[SUP] 1 2 3 4 [/SUP], Jennifer Franz[SUP] 2 4 [/SUP], Oliver A Cornely[SUP] 2 4 5 6 7 [/SUP], Florian Kron[SUP] 8 9 10 11 12 [/SUP]
Affiliations
Abstract
Purpose: First detected in China in 2019, the novel coronavirus disease (COVID-19) has rapidly spread globally. Since then, healthcare systems are exposed to major challenges due to scarce personnel and financial resources. Therefore, this analysis intended to examine treatment costs of COVID-19 inpatients in a German single centre during the first pandemic wave in 2020 from a healthcare payer perspective. Potential cost savings were assessed considering the administration of remdesivir according to the European Medicines Agency label.
Methods: A retrospective medical-chart review was conducted on COVID-19 patients treated at University Hospital Cologne, Germany. Patients were clustered according to an eight-category ordinal scale reflecting different levels of supplemental oxygen. Potential cost savings due to the administration of remdesivir were retrospectively modelled based on a reduced length of stay, as shown in the Adaptive COVID-19 Treatment Trial.
Results: 105 COVID-19 patients were identified. There was wide variability in the service data with median treatment costs from EUR 900 to EUR 53,000 per patient, depending on major diagnosis categories and clinical severity. No supplemental oxygen was needed in 40 patients (38.1%). Forty-three (41.0%) patients were treated in intensive-care units, and 30 (69.8%) received invasive ventilation. In our model, in-label administration of remdesivir would have resulted in costs savings of EUR 2100 per COVID-19 inpatient (excluding acquisition costs).
Conclusion: We found that COVID-19 inpatients suffer from heterogeneous disease patterns with a variety of incurred G-DRG tariffs and treatment costs. Theoretically shown in the model, financial resources can be saved by the administration of remdesivir in eligible inpatients.
Keywords: COVID-19; DRG; Real-life data; Remdesivir; SARS-CoV-2; Treatment costs.
. 2021 Aug 18.
doi: 10.1007/s15010-021-01685-8. Online ahead of print.
A cost of illness study of COVID-19 patients and retrospective modelling of potential cost savings when administering remdesivir during the pandemic "first wave" in a German tertiary care hospital
Julia Jeck[SUP] 1 [/SUP], Florian Jakobs[SUP] 1 2 3 [/SUP], Anna Kron[SUP] 1 2 3 4 [/SUP], Jennifer Franz[SUP] 2 4 [/SUP], Oliver A Cornely[SUP] 2 4 5 6 7 [/SUP], Florian Kron[SUP] 8 9 10 11 12 [/SUP]
Affiliations
- PMID: 34406606
- DOI: 10.1007/s15010-021-01685-8
Abstract
Purpose: First detected in China in 2019, the novel coronavirus disease (COVID-19) has rapidly spread globally. Since then, healthcare systems are exposed to major challenges due to scarce personnel and financial resources. Therefore, this analysis intended to examine treatment costs of COVID-19 inpatients in a German single centre during the first pandemic wave in 2020 from a healthcare payer perspective. Potential cost savings were assessed considering the administration of remdesivir according to the European Medicines Agency label.
Methods: A retrospective medical-chart review was conducted on COVID-19 patients treated at University Hospital Cologne, Germany. Patients were clustered according to an eight-category ordinal scale reflecting different levels of supplemental oxygen. Potential cost savings due to the administration of remdesivir were retrospectively modelled based on a reduced length of stay, as shown in the Adaptive COVID-19 Treatment Trial.
Results: 105 COVID-19 patients were identified. There was wide variability in the service data with median treatment costs from EUR 900 to EUR 53,000 per patient, depending on major diagnosis categories and clinical severity. No supplemental oxygen was needed in 40 patients (38.1%). Forty-three (41.0%) patients were treated in intensive-care units, and 30 (69.8%) received invasive ventilation. In our model, in-label administration of remdesivir would have resulted in costs savings of EUR 2100 per COVID-19 inpatient (excluding acquisition costs).
Conclusion: We found that COVID-19 inpatients suffer from heterogeneous disease patterns with a variety of incurred G-DRG tariffs and treatment costs. Theoretically shown in the model, financial resources can be saved by the administration of remdesivir in eligible inpatients.
Keywords: COVID-19; DRG; Real-life data; Remdesivir; SARS-CoV-2; Treatment costs.